Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ALCON's CILOXAN OPHTHALMIC CIPROFLOXACIN SOLUTION

Executive Summary

ALCON's CILOXAN OPHTHALMIC CIPROFLOXACIN SOLUTION is first quinolone antimicrobial to be approved for ocular use. The ciprofloxacin HCI 0.3% ophthalmic solution was approved on Dec. 31 for treating bacterial conjunctivitis and corneal ulcers. The NDA for Ciloxan was submitted by Alcon in July 1989. Approval took about 17 months. Miles, the innovator of the broad spectrum quinolone ciprofloxacin, markets the drug as Cipro tablets and Cipro I.V. Alcon began shipping Ciloxan on Jan. 24 and will start detailing the product to physicians by the end of February or the beginning of March. Ciloxan is available in 2.5 ml and 5 ml plastic dispensers at a price to wholesalers of $ 6.90 and $ 12.60, respectively. In a Feb. 8 release, Alcon noted that the use of Ciloxan in patients with corneal ulcers "may reduce or eliminate the need for costly hospitalization." Current corneal ulcer therapy, Alcon said, "often requires physicians or pharmacists to extemporaneously modify commercially available antimicrobials to prepare a fortified product." Merck has an NDA pending for use of a fluoroquinolone in ocular infections: Chibroxin (nonfloxacin) 0.3% ophthalmic solution. Merck markets norfloxacin tablets (Noroxin) for the treatment of urinary tract infections. Allergan reported in December that its ophthalmic ofloxacin NDA is "in the final stages of review" ("The Pink Sheet" Dec. 10, In Brief).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel